Results about: peptide synthesis
Chemists at IRB Barcelona patent and present a shuttle capable of transporting molecules into the brain; this achievement could facilitate the treatment of diseases with no therapy available.
98% of drugs targeting the central nervous system are discarded because they are unable to cross the physical barrier that protects the brain.
The IRB Barcelona scientists, together with clinical teams, are now evaluating the potential of their shuttle for rare and orphan diseases.
The Council recognizes the impact of his research in peptide chemistry with applications in innovative therapies for cancer
The "Ciutat de Barcelona" prize represents the highest recognition that gives the city to its citizens
Catalan biotech Iproteos has won the Expoquimia R+D+I Award in the Biotechnology category for the development of IPR19, a new drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.
The spin-off, founded by two IRB Barcelona scientists leaders in the field of therapeutic peptides, Teresa Tarrago and Ernest Giralt, expect to begin clinical trials of the compound in 2016.
Endowed with € 5,000 in each of their two categories -Biotechnology and Chemistry- the Expoquimia R+D+I Awards were delivered yesterday during the World Chemical Summit Night as part of the Expoquimia Exhibit at the Fair of Barcelona grounds.
The Max-Bergmann-Society, a European-based organization of German, Swiss, and Austrian chemists, seeks to promote peptide research with a special emphasis on chemical methodologies.